Compare Crocs, Inc. (CROX) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Pfizer Inc — how do they compare? Crocs, Inc. trades at $115.54 (market cap $5.60B), while Pfizer Inc trades at $27.72 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 28.3× Crocs, Inc.'s market cap, and Pfizer Inc pays a 6.18% dividend while Crocs, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crocs, Inc. for 96 Days and Pfizer Inc for 158 Days on average.
| CROX | PFE | |
|---|---|---|
Market Cap | $5.60B | $158.56B |
Volume | 1,026,773 | 44,138,282 |
Sector | Consumer Cyclical | Health |
52-Week High | $141.19 | $29.02 |
52-Week Low | $73.39 | $23.67 |
Typical Hold Time | 96 Days | 158 Days |
Enterprise Value | $7.12B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $115.20, down 4.18% amid bearish technical signals, though recent earnings beats and a 51% analyst buy rating suggest underlying strength. The stock shows attractive valuation with a P/E of 10.37 and strong profitability metrics including 57.47% gross margin and 42.3% ROE. Management is focusing on product innovation and HEYDUDE brand reset to drive growth.
Despite near-term price pressure, CROX offers value with consensus price target of $136.78 (19% upside). Risks include recent net income decline to -$81M and competitive pressures in footwear. The company's cash flow generation and brand positioning support long-term recovery potential.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
